

**ORIGINAL ARTICLE**

# Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time

Rebeca Izquierdo<sup>1,2</sup>  | Inés Suárez-García<sup>2,3,4</sup>  | Cristina Marco-Sánchez<sup>1,2</sup>  |  
 Leire Pérez-Latorre<sup>2,5</sup> | Melchor Riera<sup>2,6</sup>  | Joanna Cano<sup>7</sup> |  
 Consuelo Viladés<sup>2,8,9</sup>  | Sergio Reus<sup>10,11</sup>  | Julián Olalla<sup>12</sup>  |  
 Patricia González-Ruano<sup>3</sup> | Eva Orviz<sup>13,14</sup>  | Asunción Díaz<sup>1,2</sup>  |  
 Santiago Moreno<sup>2,15,16</sup>  | Inma Jarrín<sup>1,2</sup>  | CoRIS cohort

<sup>1</sup>National Centre for Epidemiology, Carlos III Health Institute, Madrid, Spain

<sup>2</sup>CIBERINFEC, Carlos III Health Institute, Madrid, Spain

<sup>3</sup>Infectious Diseases Group, Department of Internal Medicine, Infanta Sofia University Hospital, Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), Madrid, Spain

<sup>4</sup>Department of Medicine, European University of Madrid, Madrid, Spain

<sup>5</sup>Department of Infectious Diseases, Gregorio Marañón General University Hospital, Gregorio Marañón Institute of Health Research (IiSGM), Madrid, Spain

<sup>6</sup>Infectious Diseases Unit, Internal Medicine Department, Son Espases University Hospital, Illes Balears Health Research Institute (IdISBa), Palma de Mallorca, Spain

<sup>7</sup>Department of Infectious Diseases, La Paz - Carlos III University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

<sup>8</sup>Joan XXIII University Hospital, Institute of Health Research Pere Virgili (IISPV), Tarragona, Spain

<sup>9</sup>University Rovira i Virgili, Tarragona, Spain

<sup>10</sup>Infectious Diseases Unit, Dr Balmis University General Hospital, Health and Biomedical Research Institute of Alicante (ISABIAL), Alicante, Spain

<sup>11</sup>Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain

<sup>12</sup>Department of Internal Medicine, Costa del Sol University Hospital, Marbella, Spain

<sup>13</sup>Sandoval Health Center, Madrid, Spain

<sup>14</sup>San Carlos Clinical Hospital, Institute for Health Research San Carlos Clinical Hospital (IdISSC), Madrid, Spain

<sup>15</sup>Department of Infectious Diseases, University Hospital Ramón y Cajal, Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain

<sup>16</sup>Department of Medicine, Alcalá University, Madrid, Spain

**Correspondence**

Rebeca Izquierdo Miguel, National Centre for Epidemiology, Instituto de Salud Carlos III, Avenida Monforte de Lemos, 5, 28029, Madrid, Spain.  
 Email: [r.izquierdo@externos.isciii.es](mailto:r.izquierdo@externos.isciii.es)

**Abstract**

**Objectives:** We aimed to describe health-related quality of life (HRQoL), overall and across its dimensions, identify associated factors, and assess changes over time among people with HIV (PWH) from the Spanish multicentre CoRIS cohort.

Group authorship: Centres and investigators involved in the CoRIS cohort are listed in Appendix 0.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). *HIV Medicine* published by John Wiley & Sons Ltd on behalf of British HIV Association.

### Funding information

Instituto de Salud Carlos III, Acción Estratégica en Salud Intramural 2020, Grant/Award Number: PI20CIII/00027; CIBER – Consorcio Centro de Investigación Biomédica en Red, Grant/Award Number: CB21/13/00091; Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU

**Methods:** We developed a mobile app to collect HRQoL data every 3 months using the WHOQOL-HIV-BREF questionnaire (31 items across six domains), among PWH followed in CoRIS in 2021–2023. Factors associated with good/very good global HRQoL and with domain-specific mean scores were identified using multivariable logistic and linear regression, respectively.

**Results:** Of 414 PWH (94.2% on antiretroviral treatment, 91.1% virally suppressed), 51.2% reported good/very good HRQoL. Latin American migrants (adjusted OR: 0.60 [95% CI: 0.36; 1.00]), and participants with lower educational level (0.36 [0.21; 0.64]), a previous AIDS diagnosis (0.56 [0.29; 1.11]) and a history of non-AIDS-related cancers (0.40 [0.14; 1.14]) were less likely to report good/very good global HRQoL. The most affected items included sexual satisfaction, forgiveness and blame, sleep and rest, and concerns about the future, with spirituality, religion and personal beliefs as the most affected domain. Latin American origin, lower educational level and shorter (<2 years) or longer (>15 years) time since HIV diagnosis were associated with poorer HRQoL in specific domains. No significant changes in HRQoL were observed after 12 months except slightly higher scores in physical health.

**Conclusions:** Only half of PWH reported good/very good global HRQoL. This highlights the need to develop targeted strategies to improve HRQoL among PWH, focusing on addressing the most affected dimensions and supporting the most vulnerable groups.

### KEYWORDS

HIV, patient-reported outcome measures (PROMs), patients, health-related quality of life (HRQoL), risk factors, World Health Organization HIV Quality of Life Instrument (WHOQOL-HIV-BREF)

## INTRODUCTION

The widespread access to antiretroviral treatment (ART) has significantly increased the life expectancy of people with HIV (PWH) [1], and has transformed HIV infection into a manageable chronic condition [2]. However, despite these advances, PWH often report lower health-related quality of life (HRQoL) compared with both the general population [3–5] and individuals with other chronic conditions [6]. As a result, improving HRQoL of PWH and promoting person-centred healthcare have become key priorities for clinicians, researchers and policymakers [7, 8]. This focus is reflected in the latest global health strategy on HIV from the World Health Organization (WHO), which also highlights the importance of monitoring HRQoL among PWH [9].

In this context, there is a growing interest worldwide, particularly in high-income countries, in utilizing validated patient-reported outcomes measures (PROMs) to assess the self-reported HRQoL of PWH in clinical settings [10]. A recent meta-analysis has shown that a

variety of instruments are used to assess HRQoL in PWH, the World Health Organization HIV Quality of Life Instrument (WHOQOL-HIV) being the most widely used [11]. The WHOQOL-HIV effectively addresses HIV-specific health concerns by including items related to death, stigma, and blame for HIV status, which are unique to HIV-specific instruments compared with generic QoL tools like the 36-Item Short Form Health Survey questionnaire (SF-36) and EuroQoL-5D (EQ-5D) [11]. Furthermore, the availability of the WHOQOL-HIV in over 20 languages underscores its widespread use across diverse cultural contexts [11].

In Europe, the percentage of PWH reporting good HRQoL ranges between 63% to 76% [12, 13], which falls significantly below the Joint United Nations Programme on HIV and AIDS (UNAIDS) target of achieving 95% for good HRQoL [14]. Factors that may influence HRQoL in PWH include socioeconomic status, immunological status, presence of symptoms, comorbidities, social support and adherence to ART [15, 16]. However, the specific impact and relative importance of these factors are not

yet fully understood. Furthermore, HRQoL evolves over time, and this evolution can be affected by disease progression, adherence to ART and psychosocial interventions. Understanding these dynamics is essential for enhancing the comprehensive care provided to PWH. To our knowledge, no study to date has examined the evolution of HRQoL under real-life conditions. In Spain, most research on HRQoL in PWH has been limited to single-centre studies, primarily using the generic EQ-5D-5L tool [17–20], which may lack the sensitivity of HIV-specific PROMs designed to capture key aspects of HRQoL, such as stigma, relationship challenges and comorbidities [21]. Only four studies have assessed HRQoL using the HIV-specific instrument WHOQOL-HIV-BREF questionnaire at the national level: two focus on older PWH [22, 23], one reports data from 2016 to 2017 [24] and another examines the impact of a peer intervention on the HRQoL of people recently diagnosed with HIV [25].

The aims of our study were: (i) to describe the HRQoL, both overall and across its dimensions, using the WHOQOL-HIV-BREF questionnaire, (ii) to identify associated factors and (iii) to assess changes over time among PWH from the nationwide multicentre CoRIS cohort in Spain during the period 2021–2023.

## METHODS

### Study design and study population

This study was conducted between June 2021 and June 2023 within the framework of the Spanish CoRIS cohort. CoRIS is a prospective multicentre cohort comprising adult PWH, naive to ART at study entry, recruited since 1 January 2004 in 48 centres from 14 autonomous regions in the Spanish public healthcare system. CoRIS gathers a comprehensive dataset that includes baseline and follow-up sociodemographic, immunological and clinical data, along with data on antiretroviral medications. The data are highly standardized and subjected to annual quality control procedures. Participants undergo periodic follow-ups in line with routine clinical practice. A detailed description of the CoRIS cohort can be found elsewhere [26].

Eligible individuals were any PWH in active follow-up in CoRIS who attended their outpatient clinic during the study period.

### Data collection procedure

We designed and implemented a mobile app to routinely collect, every 3 months, data on HRQoL

measured through the self-reported WHOQOL-HIV-BREF questionnaire validated in Spanish [16]. The questionnaire comprises 31 items: 1 on global HRQoL, 1 on general health satisfaction and 29 covering six domains: physical health, psychological health, level of independence, social relationships, environmental health and spirituality, religion and personal beliefs (SRPB). Each item is rated on a five-point Likert scale, where 1 denotes very poor and 5 very good. For each domain, scores range from 4 to 20. Higher scores denote higher HRQoL.

HIV healthcare providers explained the study to the eligible participants and invited them to participate. Those who agreed were provided with an informed consent form to sign and a link to download the mobile app for smartphones and tablets through which they could answer the online version of the questionnaire. The average time to complete the questionnaire was 5 min.

The information on sociodemographic and clinical variables at the time of completion of the first questionnaire, hereafter referred to as baseline, was obtained from the CoRIS database. Sociodemographic and clinical variables considered included sex at birth (male, female, unknown), age (<35, 35–49 and ≥50 years), transmission category (homo/bisexual contact, heterosexual contact, other/unknown), region of origin (Spain, Latin America, other, unknown), educational level (upper secondary/university, no education/compulsory education, unknown), time from HIV diagnosis (<2, 2–15, >15 years), previous AIDS diagnosis (no, yes, unknown), CD4+ T cell count (≥350 cells/μL, <350 cells/μL, unknown), viral load ≤50 copies/mL (no, yes, unknown), years on ART, type of ART regimen (two nucleoside reverse transcriptase inhibitors + one integrase inhibitor, two nucleoside reverse transcriptase inhibitors + one non-nucleoside reverse transcriptase inhibitor, two nucleoside reverse transcriptase inhibitors + one protease inhibitor, dual therapy with dolutegravir plus lamivudine or rilpivirine, other combinations, unknown) and presence of comorbidities (diabetes, chronic heart disease, liver cirrhosis, history of non-AIDS-related cancer, chronic kidney disease).

### Statistical analysis

Descriptive analysis was conducted using frequency tables for categorical variables and median and interquartile range (IQR) for continuous variables. We calculated the percentage (95% confidence interval [95% CI]) of individuals rating good/very good global HRQoL and of those being satisfied/very satisfied with health,

overall and according to sociodemographic and clinical characteristics at baseline, and used multivariable logistic regression models to identify independently associated risk factors. For each item and domain of the WHOQOL-HIV-BREF questionnaire we calculated means and 95% CI and used multivariable linear regression models to identify factors associated with mean scores of each domain. Among the subset of individuals with information of HRQoL both at baseline and at 12( $\pm$ 6) months, we calculated mean changes (95% CI) for each specific domain.

All statistical analyses were performed using Stata<sup>®</sup> software (version 17.0; Stata Corporation, College Station, TX, USA).

## Ethics approval and informed consent

CoRIS cohort was approved by the Clinical Research Ethics Committee of the Gregorio Marañón General University Hospital. All patients consented to join CoRIS and to participate in this study by signing both informed consent forms. This particular study received approval from the Clinical Research Ethics Committee Carlos III Health Institute, Madrid, Spain (CEI PI 52 \_2020-v2\_Enmienda 2020-v2).

## RESULTS

### Participants' characteristics

Table 1 shows the characteristics of the 414 individuals from 21 centres included in the analyses. Of these, 91.3% were male, and the median age was 43.9 (IQR: 36.2; 51.6) years. The reported mode of HIV acquisition was homo/bisexual intercourse in 81.2% of individuals, 56.3% were from Spain and 74.2% had upper secondary or university education. The median time from HIV diagnosis was 7.3 (IQR: 3.4; 12.1) years, 11.1% had a previous AIDS diagnosis, the median CD4+ T cell count was 768 (IQR: 570; 1002) cells/ $\mu$ L and 91.1% were virologically suppressed. A total of 94.2% of participants were on ART for a median of 6.5 (IQR: 3.5; 10.3) years. Most individuals were receiving regimens consisting of two nucleoside reverse transcriptase inhibitors plus one integrase inhibitor (46.2%) or dual therapies with dolutegravir plus lamivudine or rilpivirine (31.0%). Some 4.8% of participants had a history of non-AIDS-related cancer. The characteristics of the participants in this study were comparable to those of individuals under active follow-up in the entire CoRIS cohort (data not shown).

### Global HRQoL and general health satisfaction: description and associated factors

Of 414 participants surveyed, 51.2% self-reported their global HRQoL as good or very good (Figure 1). Multivariable analyses showed that being of Latin American origin (adjusted OR: 0.60 [95% CI: 0.36; 1.00];  $p$ -value = 0.051), having no education or only compulsory education (0.36 [0.21; 0.64]; 0.001), having a previous AIDS diagnosis (0.56 [0.29; 1.11]; 0.098) and having a history of non-AIDS-related cancer (0.40 [0.14; 1.14]; 0.086) were associated with a lower chance of rating a good/very good global HRQoL (Table 2).

Some 64.7% of participants were satisfied or very satisfied with their health (Figure 1). Multivariable analyses indicated that having no or compulsory education (0.41 [0.24; 0.71]; 0.002) and a CD4+ T cell count of <350 cells/ $\mu$ L (0.39 [0.17; 0.91]; 0.030) were associated with a significantly lower likelihood of being satisfied/very satisfied with health (Table 2).

### HRQoL-specific domains: mean scores and associated factors

Mean scores for each item and domain of the WHOQOL-HIV-BREF are shown in Figure 2. The items with the lowest scores were sexual satisfaction (mean: 3.1 [95% CI: 3.0; 3.2]), forgiveness and blame (3.1 [2.9; 3.2]), sleep and rest (3.2 [3.1; 3.3]) and concerns about the future (3.2 [3.0; 3.3]). In contrast, the items with the highest scores were mobility (4.4 [4.3; 4.5]), information for daily living (4.1 [4.0; 4.1]) and accessibility of health services (4.1 [4.0; 4.2]) (Figure 2a). Across domains, level of independence (15.4 [15.1; 15.7]) and environmental health (15.2 [15.0; 15.7]) showed the highest scores, while the SRPB domain presented the lowest score (13.4 [13.1; 13.8]) (Figure 2b).

Table 3 shows the adjusted mean differences in specific domain scores according to sociodemographic and clinical characteristics. Results from multivariable analyses showed that individuals born in Latin America had significantly poorer physical (adjusted mean difference:  $-0.87$  [95% CI:  $-2.66$ ;  $-1.09$ ]), level of independence ( $-0.78$  [ $-1.49$ ;  $-0.06$ ]), social ( $-1.04$  [ $-1.87$ ;  $-0.22$ ]) and environmental ( $-0.98$  [ $-1.59$ ;  $-0.37$ ]) HRQoL than those born in Spain. Having no or compulsory education was also associated with poorer psychological ( $-0.80$  [ $-1.54$ ;  $-0.07$ ]), level of independence ( $-0.72$  [ $-1.48$ ;  $0.05$ ]) and environmental ( $-1.35$  [ $-2.00$ ;  $-0.70$ ]) HRQoL compared with having upper secondary or university education. Compared with individuals who had been diagnosed

**TABLE 1** Sociodemographic and clinical characteristics at baseline of 414 individuals included.

Characteristic	Value
Sex at birth, <i>n</i> (%)	
Male	378 (91.3)
Female	35 (8.5)
Unknown	1 (0.2)
Age, years	
Median (IQR)	43.9 (36.2–51.6)
<35	89 (21.5)
35–49	206 (49.8)
≥50	119 (28.7)
Transmission category, <i>n</i> (%)	
Homo/bisexual contact	336 (81.2)
Heterosexual contact	59 (14.3)
Other/Unknown	19 (4.6)
Region of origin, <i>n</i> (%)	
Spain	233 (56.3)
Latin America	103 (24.9)
Other <sup>a</sup>	75 (18.1)
Unknown	3 (0.7)
Educational level, <i>n</i> (%)	
Upper secondary/university	307 (74.2)
No education/compulsory education	71 (17.1)
Unknown	36 (8.7)
Time from HIV diagnosis, years	
Median (IQR)	7.3 (3.4–12.1)
<2	74 (17.9)
2–15	285 (68.8)
>15	55 (13.3)
Previous AIDS diagnosis, <i>n</i> (%)	
No	366 (88.4)
Yes	46 (11.1)
Unknown	2 (0.5)
CD4+ T, cells/μL	
Median (IQR)	768 (570–1002)
≥350	367 (88.6)
<350	30 (7.2)
Unknown	17 (4.1)
Viral load ≤ 50 copies/mL, <i>n</i> (%)	
Yes	377 (91.1)
No	22 (5.3)
Unknown	15 (3.6)
On ART, <i>n</i> (%)	
No	24 (5.8)

(Continues)

**TABLE 1** (Continued)

Characteristic	Value
Yes	390 (94.2)
Years on ART, median (IQR)	6.5 (3.5; 10.3)
Type of ART regimen, <i>n</i> (%)	
2 NRTI + 1 integrase inhibitor	180 (46.2)
2 NRTI + 1 NNRTI	48 (12.3)
2 NRTI + 1 PI	10 (2.6)
Dual therapy: DTG plus 3TC or RPV	121 (31.0)
Other combinations	16 (4.1)
Unknown	15 (3.8)
Comorbidities, <i>n</i> (%)	
Diabetes	10 (2.4)
Chronic heart disease	12 (2.9)
Liver cirrhosis	0 (0)
History of non-AIDS-related cancer	20 (4.8)
Chronic kidney disease	5 (1.2)


Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; DTG, dolutegravir; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RPV, rilpivirine.

<sup>a</sup>Other: 65 from Western European countries other than Spain, 6 from Eastern Europe, 1 from India, 1 from Australia and 2 from the Philippines.

with HIV for 2–15 years, those diagnosed for less than 2 years reported significantly lower psychological (−1.04 [−1.86; −0.21]) and SRPB (−1.43 [−2.47; −0.39]) scores, and those diagnosed for >15 years reported lower scores for psychological (−0.89 [−1.45; −0.03]) and social (−0.88 [−1.90; 0.14]) HRQoL.

## Changes in HRQoL after 12 months

A total of 105 participants had information on HRQoL at 12 months after baseline. Those who reported HRQoL data at 12 months were similar to those who did not, except that they were more likely to be older and born in Spain. The percentage of individuals rating their global HRQoL as good/very good increased from 56.2% to 63.8% at 12 months from baseline (*p*-value = 0.131). However, the percentage of those being satisfied/very satisfied with their health remained similar at baseline (67.6%) and after 12 months (68.6%) (*p*-value = 0.828) (data not shown). Regarding the evolution of the scores of the different domains, we failed to find significant differences in the domain-specific mean scores at 12 months from baseline, except that we observed slightly higher scores in physical health (mean change: 0.48 [95% CI: 0.05; 0.90]; *p*-value = 0.029) (Table 4).



**FIGURE 1** Distribution of participants' responses regarding their global health-related quality of life (HRQoL) and satisfaction with their health.

## DISCUSSION

In the present study, around half of the PWH reported good or very good global HRQoL and nearly two-thirds were satisfied or very satisfied with their health. In contrast, nearly one in five participants reported poor or very poor quality of life, while one in nine expressed dissatisfaction or extreme dissatisfaction with their health. The most affected items included sexual satisfaction, forgiveness and blame, sleep and rest, and concerns about the future, with SRPB as the most affected domain. Additionally, participants from Latin America and those with lower levels of education showed poorer HRQoL globally and across most of the dimensions. Low satisfaction with health was specifically associated with having a lower level of education and a lower CD4+ T cell count. Changes in HRQL observed over a 1-year follow-up period were modest.

Compared with previous studies conducted in Europe using the WHOQOL-VIH-BREF, the percentage of participants in our study who self-reported good or very good global HRQoL was slightly lower [12, 13]. Additionally, health satisfaction in our study was similar to that found in France [12] and better than in Portugal [27]. These differences are probably due to variations in social support systems, healthcare access and societal attitudes towards HIV: these contextual factors can shape the way individuals experience and report HRQoL.

Sexual satisfaction and sleep quality were the most affected items in our study, consistent with findings from Spain and Finland using the same HRQoL scale [24, 28]. Previous studies have found that sexual dissatisfaction is common among men with HIV in Europe and is strongly

linked to psychological and social well-being [29]. Additionally, poor sleep quality among PWH has been frequently reported, with anxiety, ART medication type, and family and social support identified as key factors influencing sleep quality [30].

The main factors associated with poorer global HRQoL and specific domains were Latin American origin and lower educational level. Latin American-born individuals had significantly poorer scores in physical, independence, social and environmental HRQoL compared with those born in Spain, which explains the association with worse global HRQoL. The reasons for this are probably complex and could be explained by cultural factors, lack of social or family support, the experience of immigration itself, or inequalities in access to health services, among others [31]. Although all residents in Spain have access to the national health system, difficulties and inequalities in access to health services have been found among migrants in Spain [32]. Similar to our study, foreign-born individuals in France reported lower physical HRQoL [12], whereas no significant differences by nationality in HRQoL domains were observed in Finland [13].


A recent meta-analysis identified education as a key social determinant of HRQoL among PWH [16]. The education level in our study was higher than that in the general Spanish population, in which 53.8% adults have upper secondary or university education [33]. Our study found that a higher educational level was associated with better scores in global HRQoL, health satisfaction and level of independence, psychological and environmental domains, consistent with prior research in Spain [24]. Similarly, studies in France and Georgia found that

**TABLE 2** Odds ratios (95% CI) for the association between sociodemographic and clinical characteristics at baseline with good/very good global health-related quality of life (HRQoL) and with being satisfied/very satisfied with health.


Sex at birth	Good/very good global HRQoL					Satisfied/very satisfied with health				
	n [%]	Univariable		Multivariable <sup>a</sup>		n [%]	Univariable		Multivariable <sup>a</sup>	
		OR [95% CI]	P-value	OR [95% CI]	P-value		OR [95% CI]	P-value	OR [95% CI]	P-value
Male	197 [52.1]	1.00		1.00		243 [64.3]	1.00		1.00	
Female	15 [42.9]	0.69 [0.34; 1.39]	0.297	0.65 [0.25; 1.72]	0.390	24 [68.6]	1.21 [0.58; 2.55]	0.612	1.25 [0.45; 3.48]	0.670
Age, years										
<35	44 [49.4]	1.00		1.00		54 [60.7]	1.00		1.00	
35–49	113 [54.8]	1.24 [0.76; 2.04]	0.392	1.02 [0.57; 1.81]	0.951	138 [67.0]	1.32 [0.79; 2.20]	0.297	1.05 [0.58; 1.89]	0.872
≥50	55 [46.2]	0.88 [0.51; 1.52]	0.646	0.73 [0.36; 1.45]	0.361	76 [63.9]	1.15 [0.65; 2.02]	0.638	0.87 [0.43; 1.77]	0.697
Transmission category										
Homo/bisexual contact	172 [51.2]	1.00		1.00		214 [63.7]	1.00		1.00	
Heterosexual contact	28 [47.5]	0.86 [0.49; 1.50]	0.597	1.20 [0.55; 2.60]	0.650	41 [69.5]	1.30 [0.71; 2.36]	0.391	1.29 [0.57; 2.93]	0.540
Region of origin										
Spain	130 [55.8]	1.00		1.00		155 [66.5]	1.00		1.00	
Latin America	46 [44.7]	0.64 [0.40; 1.02]	0.060	0.60 [0.36; 1.00]	0.051	61 [59.2]	0.73 [0.45; 1.18]	0.199	0.79 [0.46; 1.35]	0.389
Other	36 [48.0]	0.73 [0.43; 1.23]	0.240	0.64 [0.36; 1.13]	0.122	49 [65.3]	0.95 [0.55; 1.64]	0.850	0.89 [0.49; 1.61]	0.696
Educational level										
Upper secondary/university	169 [55.0]	1.00		1.00		206 [67.1]	1.00		1.00	
No education/compulsory education	23 [32.4]	0.39 [0.23; 0.68]	0.001	0.36 [0.21; 0.64]	0.001	34 [47.9]	0.45 [0.27; 0.76]	0.003	0.41 [0.24; 0.71]	0.002
Time from HIV diagnosis, years										
<2	35 [47.3]	0.81 [0.48; 1.35]	0.414	0.70 [0.38; 1.30]	0.255	40 [54.0]	0.56 [0.33; 0.94]	0.029	0.61 [0.33; 1.15]	0.126
2–15	150 [52.6]	1.00		1.00		193 [67.7]	1.00		1.00	
>15	27 [49.1]	0.87 [0.49; 1.55]	0.631	0.95 [0.50; 1.81]	0.884	35 [63.6]	0.83 [0.46; 1.52]	0.556	0.86 [0.44; 1.66]	0.643
Previous AIDS diagnosis										
No	191 [52.2]	1.00		1.00		239 [65.3]	1.00		1.00	
Yes	19 [41.3]	0.64 [0.35; 1.20]	0.166	0.56 [0.29; 1.11]	0.098	28 [60.9]	0.83 [0.44; 1.55]	0.554	0.89 [0.44; 1.76]	0.727
CD4+ T, cells/μL										
≥350	193 [52.6]	1.00		1.00		244 [66.5]	1.00		1.00	
<350	12 [40.0]	0.60 [0.28; 1.28]	0.188	0.77 [0.33; 1.79]	0.539	11 [36.7]	0.29 [0.13; 0.63]	0.002	0.39 [0.17; 0.91]	0.030
Viral load ≤50 copies/mL										
Yes	194 [51.5]	1.00		1.00		245 [65.0]	1.00		1.00	
No	12 [54.5]	1.13 [0.48; 2.68]	0.778	1.62 [0.62; 4.23]	0.324	12 [54.5]	0.65 [0.27; 1.54]	0.323	0.82 [0.31; 2.19]	0.699
History of non-AIDS-related cancer										
No	206 [52.3]	1.00		1.00		256 [65.0]	1.00		1.00	
Yes	6 [30.0]	0.39 [0.15; 1.04]	0.060	0.40 [0.14; 1.14]	0.086	12 [60.0]	0.81 [0.32; 2.02]	0.650	1.05 [0.38; 2.92]	0.919

Abbreviations: CI, confidence interval; HRQoL, health-related quality of life; OR, odds ratio.

<sup>a</sup>Multivariable logistic regression models included sex at birth (male, female, unknown), age (<35, 35–49, ≥50 years), transmission category (homo/bisexual contact, heterosexual contact, other/unknown), region of origin (Spain, Latin America, other, unknown), educational level (upper secondary/university, no education/compulsory education, unknown), time from HIV diagnosis (<2, 2–15, >15 years), previous AIDS diagnosis (no, yes, unknown), CD4+ T cell count (≥350 cells/μL, <350 cells/μL, unknown), viral load ≤50 copies/mL (no, yes, unknown) and history of non-AIDS-related cancer (no, yes) at baseline.



\*SRPB: Spirituality, religion and personal beliefs



\*SRPB: Spirituality, religion and personal beliefs

**FIGURE 2** Mean scores (95% CI) for each item (a) and domain (b) of the WHOQOL-HIV-BREF questionnaire.

higher education levels were associated with better general, social and environmental HRQoL [12, 34], while no such relationship was observed in Finland [13]. This finding may be explained by the fact that higher education

levels often provide greater employment opportunities and social support, contributing to a more positive self-perception of HRQoL [34]. Additionally, in Spain, PWH from non-European countries and those with lower

**TABLE 3** Adjusted mean differences in the domain scores of the WHOQOL-HIV-BREF questionnaire according to sociodemographic and clinical characteristics at baseline.

Characteristic	Physical health		Psychological health		Level of independence		Social relationships		Environmental health		SRPB	
	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value
Sex at birth												
Male	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
Female	0.28 [-1.18; 1.73]	0.706	0.03 [-1.26; 1.31]	0.969	0.27 [-1.06; 1.60]	0.694	0.13 [-1.39; 1.65]	0.866	-0.38 [-1.51; 0.75]	0.509	0.59 [-1.04; 2.21]	0.477
Age, years												
<35	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
35-49	-0.09 [-0.96; 0.77]	0.829	0.35 [-0.41; 1.11]	0.365	-0.14 [-0.93; 0.65]	0.731	-0.21 [-1.12; 0.69]	0.643	0.37 [-0.29; 1.04]	0.273	-0.35 [-1.31; 0.61]	0.478
≥50	-0.29 [-1.32; 0.75]	0.588	0.17 [-0.75; 1.09]	0.715	-0.29 [-1.24; 0.65]	0.542	-0.78 [-1.86; 0.31]	0.162	0.22 [-0.59; 1.02]	0.594	-0.42 [-1.58; 0.73]	0.474
Transmission category												
Homo/bisexual contact	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
Heterosexual contact	-0.21 [-1.38; 0.95]	0.717	0.27 [-0.76; 1.30]	0.603	-0.41 [-1.47; 0.66]	0.452	0.01 [-1.20; 1.23]	0.981	0.43 [-0.47; 1.34]	0.345	-0.26 [-1.55; 1.04]	0.696
Region of origin												
Spain	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
Latin America	-1.87 [-2.66; -1.09]	<0.001	-0.19 [-0.88; 0.50]	0.591	-0.78 [-1.49; -0.06]	0.035	-1.04 [-1.87; -0.22]	0.013	-0.98 [-1.59; -0.37]	0.002	-0.90 [-1.77; -0.02]	0.045
Other	-2.75 [-3.62; -1.89]	<0.001	0.05 [-0.71; 0.81]	0.900	-0.08 [-0.87; 0.70]	0.833	-0.09 [-0.99; 0.81]	0.842	-0.18 [-0.84; 0.49]	0.601	-0.85 [-1.81; 0.11]	0.082
Educational level												
Upper secondary/university	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
No education/compulsory education	-0.43 [-1.27; 0.41]	0.313	-0.80 [-1.54; -0.07]	0.033	-0.72 [-1.48; 0.05]	0.065	-0.27 [-1.15; 0.61]	0.544	-1.35 [-2.00; -0.70]	<0.001	-0.23 [-1.16; 0.70]	0.628
Time from HIV diagnosis, years												
<2	-0.12 [-1.05; 0.82]	0.807	-1.04 [-1.86; -0.21]	0.014	-0.65 [-1.51; 0.20]	0.134	-0.08 [-1.05; 0.90]	0.880	-0.25 [-0.97; 0.48]	0.503	-1.43 [-2.47; -0.39]	0.007
2-15	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
>15	-0.60 [-1.58; 0.37]	0.224	-0.89 [-1.75; -0.03]	0.042	-0.69 [-1.58; 0.19]	0.125	-0.88 [-1.90; 0.14]	0.089	-0.52 [-1.27; 0.23]	0.176	-0.27 [-1.35; 0.82]	0.628
Previous AIDS diagnosis												
No	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
Yes	-0.31 [-1.33; 0.71]	0.550	0.13 [-0.77; 1.02]	0.782	-0.32 [-1.25; 0.61]	0.501	0.55 [-0.52; 1.61]	0.314	-0.20 [-0.99; 0.59]	0.620	0.67 [-0.46; 1.80]	0.245
CD4+ T <sub>h</sub> cells/μL												
≥350	Ref.		Ref.		Ref.		Ref.		Ref.		Ref.	
<350	-0.87 [-2.13; 0.40]	0.178	-0.17 [-1.29; 0.95]	0.766	-0.68 [-1.84; 0.47]	0.247	-0.49 [-1.82; 0.83]	0.463	0.48 [-0.50; 1.46]	0.336	-0.78 [-2.19; 0.63]	0.276

(Continues)

TABLE 3 (Continued)

Characteristic	Physical health		Psychological health		Level of independence		Social relationships		Environmental health		SRPB	
	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value	Mean difference [95% CI]	P-value
Viral load $\leq 50$ copies/mL												
Yes	Ref.	0.378	Ref.	0.291	Ref.	0.772	Ref.	0.384	Ref.	0.720	Ref.	0.394
No	0.65 [-0.79; 2.09]		0.68 [-0.59; 1.95]		-0.19 [-1.51; 1.12]		0.67 [-0.84; 2.18]		0.20 [-0.91; 1.32]		0.70 [-0.91; 2.30]	
History of non-AIDS-related cancer												
No	Ref.	0.663	Ref.	0.737	Ref.	0.144	Ref.	0.714	Ref.	0.361	Ref.	0.758
Yes	0.33 [-1.16; 1.83]		-0.23 [-1.55; 1.10]		-1.02 [-2.39; 0.35]		0.29 [-1.27; 1.86]		-0.54 [-1.70; 0.62]		-0.26 [-1.93; 1.41]	

Note: Multivariable linear regression models included sex at birth (male, female, unknown), age (<35, 35–49 and  $\geq 50$  years), transmission category (homo/bisexual contact, heterosexual contact, other/unknown), region of origin (Spain, Latin America, other, unknown), educational level (upper secondary/university, no education/compulsory education, unknown), time from HIV diagnosis (<2, 2–15, >15 years), previous AIDS diagnosis (no, yes, unknown), CD4+ T cell count ( $\geq 350$  cells/ $\mu\text{L}$ , <350 cells/ $\mu\text{L}$ , unknown), viral load  $\leq 50$  copies/mL (no, yes, unknown) and history of non-AIDS-related cancer (no, yes) at baseline. Abbreviations: CI, confidence interval; Ref., reference; SRPB, spirituality, religion and personal beliefs.

educational levels have been shown to have a higher risk of late presentation [35], which may lead to poorer global HRQoL and lower scores in specific domains for these vulnerable groups.

Regarding clinical factors, while a lower CD4+ T cell count was associated with a reduced health satisfaction, no significant associations were found between immunological or virological status and other HRQoL domains, consistent with studies from France, Finland and Portugal [12, 13, 27]. This may be attributed to advancements in prognosis and effective treatments that reduce psychological distress related to immunodeficiency [12]. In contrast, prior research has found that higher CD4+ T cell counts are associated with better levels of independence and physical HRQoL in Spain [24], whereas in Georgia, they are linked to improved scores in physical and environmental HRQoL as well as in the SRPB domains [34].

Our findings revealed lower psychological and SRPB scores among participants diagnosed with HIV less than 2 years ago, likely reflecting the need for an adaptation period following the initial emotional impact of the diagnosis [36]. In contrast, those diagnosed more than 15 years ago had poorer psychological and social HRQoL, which may be partly due to their diagnosis during a time of poorer prognosis [4] and an increased risk of age-related diseases [37], both of which may have adversely affected their HRQoL, mental health and social functioning. Similarly, a French study found that individuals diagnosed either recently or for over 5 years had poorer HRQoL than those diagnosed 2–5 years ago [12]. Conversely, while previous research in Spain reported negative correlations between HRQoL dimensions and years since diagnosis [24], no such correlations were observed in Finland [13]. Furthermore, previous European studies have identified associations between good HRQoL and being male, older and having an undetectable viral load [13, 24]. However, our results did not show a significant association with these factors.

Regarding changes in HRQoL over time, the observed variations were modest, with a slight increase in the proportion of individuals rating their global HRQoL as good or very good, along with improved scores in the physical domain at 12 months. These findings, which suggest that HRQoL remains relatively stable over a year of routine clinical follow-up, should be interpreted with caution, as only a quarter of the participants had HRQoL at 12 months. Long-term studies are needed to gain a more comprehensive understanding. Monitoring HRQoL progression could help healthcare providers in identifying areas requiring intervention and evaluating the impact of HIV management strategies.

Our study has several limitations. First, the generalizability of our results may be limited by potential selection

**TABLE 4** Mean domain scores at baseline and after 12 months, and mean changes from baseline to 12 months.

Parameter	Mean [95% CI]			P-value
	Baseline	12 months	Mean change [95% CI]	
Physical health	14.77 [14.20; 15.34]	15.25 [14.68; 15.82]	0.48 [0.05; 0.90]	0.029
Psychological health	14.42 [13.86; 14.99]	14.15 [13.55; 14.75]	-0.27 [-0.69; 0.15]	0.198
Level of independence	15.58 [15.00; 16.16]	15.32 [14.77; 15.88]	-0.26 [-0.74; 0.22]	0.291
Social relations	14.56 [13.87; 15.26]	14.65 [13.96; 15.34]	0.09 [-0.41; 0.58]	0.730
Environmental health	15.61 [15.10; 16.12]	15.65 [15.19; 16.12]	0.04 [-0.30; 0.38]	0.826
SRPB	13.50 [12.79; 14.20]	13.49 [12.83; 14.14]	-0.01 [-0.49; 0.47]	0.969

Abbreviations: CI, confidence interval; SRPB, spirituality, religion and personal beliefs.

and non-response biases; however, the study sample is representative of the individuals under active follow-up in the entire CoRIS cohort. Second, since both exposure and outcome variables were measured simultaneously, we were unable to assess the directionality of the associations. Third, due to the reduced number of participants with HRQoL data at 12 months from baseline, the results of the analysis on changes in HRQoL over time should be interpreted with caution. The main strengths of our study include the use of data from a national multicentre cohort, which is reasonably representative of new HIV diagnoses in Spain [38] and adheres to strict quality control criteria. To our knowledge, this is the first study to assess HRQoL evolution during routine HIV follow-up in a real-world setting. Our findings highlight the importance of integrating HRQoL measures into routine clinical practice, as this can enhance clinical decision-making, improve symptom recognition, facilitate patient-clinician communication, and help identify and address quality-of-life-related issues [39].

## CONCLUSIONS

In conclusion, we have described overall HRQoL and its dimensions, identified associated factors, and assessed changes over time among PWH in a large multicentre cohort in Spain. We found that only half of the PWH reported good or very good global HRQoL, while nearly one in five reported poor or very poor HRQoL, falling significantly short of the target set by UNAIDS [14]. Sexual satisfaction, forgiveness and blame, sleep quality, and future concerns were the most affected items of HRQoL. Participants born in Latin America and those with lower educational level showed poorer global and specific HRQoL domains. These finding highlights the need to develop targeted strategies to improve HRQoL among PWH, focusing on addressing the most affected dimensions and supporting the most vulnerable groups.

## AUTHOR CONTRIBUTIONS

All authors were involved in the setting up of the cohort and contributed to its design. All authors were involved in data collection. IJ asked the research question, designed the study and analysed the data. IJ and RI interpreted the data. RI and IJ wrote the first draft of the paper. All authors were involved in interpretation of the data and commented on interim drafts. All authors have read and approved the final draft.

## ACKNOWLEDGEMENTS

This study would not have been possible without the collaboration of all patients, medical and nursing staff, and data managers who participated in the project.

## FUNDING INFORMATION

This study was funded by the Instituto de Salud Carlos III (Acción Estratégica en Salud Intramural 2020, PI20CIII/00027). CoRIS cohort is supported by CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB21/13/00091), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU.

## CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to declare.

## DATA AVAILABILITY STATEMENT








The original contributions presented in the study are included in the article; further inquiries should be directed to the corresponding author(s).

## ORCID

Rebeca Izquierdo  <https://orcid.org/0000-0001-5780-4462>

Inés Suárez-García  <https://orcid.org/0000-0002-7016-716X>

Cristina Marco-Sánchez  <https://orcid.org/0009-0000-2799-0890>

Melchor Riera  <https://orcid.org/0000-0002-0887-8710>  
 Consuelo Viladés  <https://orcid.org/0000-0002-2991-9593>  
 Sergio Reus  <https://orcid.org/0000-0002-3320-9754>  
 Julián Olalla  <https://orcid.org/0000-0002-8577-3891>  
 Eva Orviz  <https://orcid.org/0000-0002-2684-3431>  
 Asunción Díaz  <https://orcid.org/0000-0002-8309-4270>  
 Santiago Moreno  <https://orcid.org/0000-0002-2843-1094>  
 Inma Jarrín  <https://orcid.org/0000-0002-7485-2252>

## REFERENCES

- Jarrín I, Rava M, Del Romero Raposo J, et al. Life expectancy of people with HIV on antiretroviral therapy in Spain. *AIDS*. 2024;38(3):387-395. doi:10.1097/QAD.0000000000003772
- Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. *Lancet*. 2013;382(9903):1525-1533. doi:10.1016/S0140-6736(13)61809-7
- Langebeek N, Kooij KW, Wit FW, et al. Impact of comorbidity and ageing on health-related quality of life in HIV-positive and HIV-negative individuals. *AIDS*. 2017;31(10):1471-1481. doi:10.1097/QAD.0000000000001511
- Miners A, Phillips A, Kreif N, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. *Lancet HIV*. 2014;1(1):e32-e40. doi:10.1016/S2352-3018(14)70018-9
- Skogen V, Rohde GE, Langseth R, Rysstad O, Sørbye T, Lie B. Factors associated with health-related quality of life in people living with HIV in Norway. *Health Qual Life Outcomes*. 2023; 21(1):14. doi:10.1186/s12955-023-02098-x
- Engelhard EAN, Smit C, Van Dijk PR, et al. Health-related quality of life of people with HIV: an assessment of patient related factors and comparison with other chronic diseases. *AIDS*. 2018;32(1):103-112. doi:10.1097/QAD.0000000000001672
- Lazarus JV, Cascio M, Anderson J, Pasanen S, Harding R. A person-centred approach to enhance the long-term health and wellbeing of people living with HIV in Europe. *J Int AIDS Soc*. 2023;26(S1):e26117. doi:10.1002/jia2.26117
- Lazarus JV, Van Hout MC, Fuster-RuizdeApodaca MJ, et al. A call for health systems to monitor the health-related quality of life of people living with HIV. *HIV Med*. 2023;24(2):107-110. doi:10.1111/hiv.13427
- World Health Organization (WHO). *Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022–2030*. World Health Organization; 2022.
- Wen H, Yang Z, Zhu Z, Han S, Zhang L, Hu Y. Psychometric properties of self-reported measures of health-related quality of life in people living with HIV: a systematic review. *Health Qual Life Outcomes*. 2022;20(1):5. doi:10.1186/s12955-021-01910-w
- Zhang Y, He C, Peasgood T, et al. Use of quality-of-life instruments for people living with HIV: a global systematic review and meta-analysis. *J Int AIDS Soc*. 2022;25(4):e25902. doi:10.1002/jia2.25902
- Barger D, Hessamfar M, Neau D, et al. Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018–2020 (ANRS CO3 AQUIVIH-NA cohort: QuAlIV study). *Sci Rep*. 2023;13(1):16535. doi:10.1038/s41598-023-43434-x
- Nobre N, Pereira M, Roine RP, Sintonen H, Sutinen J. Factors associated with the quality of life of people living with HIV in Finland. *AIDS Care*. 2017;29(8):1074-1078. doi:10.1080/09540121.2017.1281879
- Joint United Nations Programme on HIV/AIDS (UNAIDS). *Understanding Fast-Track. Accelerating Action to End the AIDS Epidemic by 2030*. UNAIDS; 2015.
- Degroote S, Vogelaers D, Vandijck DM. What determines health-related quality of life among people living with HIV: an updated review of the literature. *Arch Public Health*. 2014; 72(1):40. doi:10.1186/2049-3258-72-40
- Ghiasvand H, Higgs P, Noroozi M, et al. Social and demographic determinants of quality of life in people who live with HIV/AIDS infection: evidence from a meta-analysis. *Biodemography Soc Biol*. 2020;65(1):57-72. doi:10.1080/19485565.2019.1587287
- Contreras-Macías E, Gutiérrez-Pizarra A, Robustillo-Cortés MA, Morillo-Verdugo R, UGC Farmacia, Hospital Universitario Virgen de Valme, Sevilla, Spain. High level of medication regimen complexity index correlate with worse quality of life in people living with HIV. *Rev Esp Quimioter*. 2021;34(2):93-99. doi:10.37201/req/097.2020
- Fuster-RuizdeApodaca MJ, Sánchez-Vega N, Galindo MJ, et al. The influence of patient experience with healthcare on the health-related quality of life of people living with HIV: an observational cross-sectional survey. *Infect Dis Ther*. 2019;8(3): 369-382. doi:10.1007/s40121-019-0252-3
- García-López YL, Bernal-Soriano MC, Torrés-Tendero D, Delgado de los Reyes JA, Castejón-Bolea R. Factores relacionados con la calidad de vida en personas que viven con el VIH en Alicante. *España Enfermedades Infecc Microbiol Clínica*. 2021; 39(3):127-133. doi:10.1016/j.eimc.2020.03.005
- Kall M, Fresán U, Guy D, et al. Quality of life in people living with HIV in Romania and Spain. *BMC Infect Dis*. 2021;21(S2): 898. doi:10.1186/s12879-021-06567-w
- Cooper V, Clatworthy J, Harding R, et al. Measuring quality of life among people living with HIV: a systematic review of reviews. *Health Qual Life Outcomes*. 2017;15(1):220. doi:10.1186/s12955-017-0778-6
- Nuño N, Martínez A, Martínez S, Cobos M, Hernández JS, Polo R. Sex differences in health-related quality of life and poverty risk among older people living with HIV in Spain: a cross-sectional study. *PLoS One*. 2024;19(5):e0301335. doi:10.1371/journal.pone.0301335
- Nuño N, Martínez A, Martínez S, Cobos M, Hernández JS, Polo R. Factors influencing the health-related quality of life of older men and women living with HIV in Spain. *AIDS Care*. 2024;36:1-11. doi:10.1080/09540121.2024.2361815
- Fuster-RuizdeApodaca MJ, Laguía A, Safreed-Harmon K, et al. Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF. *Health Qual Life Outcomes*. 2019;17(1):144. doi:10.1186/s12955-019-1208-8
- Fuster-RuizdeApodaca MJ, Pérez-Garín D, Baceiredo V, et al. Evaluation of a peer intervention project in the hospital setting to improve the health-related quality of life of recently diagnosed people with HIV infection. *Health Qual Life Outcomes*. 2023;21(1):106. doi:10.1186/s12955-023-02185-z

26. Sobrino-Vegas P, Gutiérrez F, Berenguer J, et al. La cohorte de la red española de investigación en sida y su biobanco: organización, principales resultados y pérdidas al seguimiento. *Enfermedades Infecc Microbiol Clínica*. 2011;29(9):645-653. doi: [10.1016/j.eimc.2011.06.002](https://doi.org/10.1016/j.eimc.2011.06.002)
27. Pereira M, Martins A, Alves S, Canavarró MC. Assessing quality of life in middle-aged and older adults with HIV: psychometric testing of the WHOQOL-HIV-Bref. *Qual Life Res*. 2014; 23(9):2473-2479. doi: [10.1007/s11136-014-0707-7](https://doi.org/10.1007/s11136-014-0707-7)
28. Nobre N, Pereira M, Sutinen J, Canavarró MC, Sintonen H, Roine RP. Quality of life of people living with HIV/AIDS: a cross-country comparison study of Finland and Portugal. *AIDS Care*. 2016;28(7):873-877. doi: [10.1080/09540121.2016.1147016](https://doi.org/10.1080/09540121.2016.1147016)
29. De Ryck I, Van Laeken D, Nöstlinger C, Platteau T, Colebunders R, The Eurosupport Study Group. Sexual satisfaction among men living with HIV in Europe. *AIDS Behav*. 2012; 16(1):225-230. doi: [10.1007/s10461-011-9987-x](https://doi.org/10.1007/s10461-011-9987-x)
30. Ren J, Zhao M, Liu B, et al. Factors associated with sleep quality in HIV. *J Assoc Nurses AIDS Care*. 2018;29(6):924-931. doi: [10.1016/j.jana.2018.04.006](https://doi.org/10.1016/j.jana.2018.04.006)
31. Ministerio De Sanidad Y Consumo. *La prevención de la infección del VIH/SIDA en la población inmigrante*. Madrid; 2006.
32. Llop-Gironés A, Vargas Lorenzo I, Garcia-Subirats I, Aller MB, Vázquez Navarrete ML. Acceso a los servicios de salud de la población inmigrante en España. *Rev Esp Salud Pública*. 2014; 88(6):715-734. doi: [10.4321/S1135-57272014000600005](https://doi.org/10.4321/S1135-57272014000600005)
33. Instituto Nacional de Estadística (INE). INEbase. n.d. Available from: <https://www.ine.es/dyngs/INEbase/listaoperaciones.htm> [Last accessed: 12/4/2024].
34. Karkashadze E, Gates MA, Chkhartishvili N, DeHovitz J, Tsertsvadze T. Assessment of quality of life in people living with HIV in Georgia. *Int J STD AIDS*. 2017;28(7):672-678. doi: [10.1177/0956462416662379](https://doi.org/10.1177/0956462416662379)
35. Rava M, Domínguez-Domínguez L, Bisbal O, et al. Late presentation for HIV remains a major health issue in Spain: results from a multicenter cohort study, 2004–2018. *PLoS One*. 2021; 16(4):e0249864. doi: [10.1371/journal.pone.0249864](https://doi.org/10.1371/journal.pone.0249864)
36. Remien RH, Mellins CA. Long-term psychosocial challenges for people living with HIV: let's not forget the individual in our global response to the pandemic. *AIDS*. 2007;21(Suppl. 5):S55-S63. doi: [10.1097/01.aids.0000298104.02356.b3](https://doi.org/10.1097/01.aids.0000298104.02356.b3)
37. Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. *Curr Opin HIV AIDS*. 2016;11(5):527-536. doi: [10.1097/COH.0000000000000305](https://doi.org/10.1097/COH.0000000000000305)
38. Vourli G, Pharris A, Cazein F, et al. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? *AIDS*. 2019;33(1):133-143. doi: [10.1097/QAD.0000000000002034](https://doi.org/10.1097/QAD.0000000000002034)
39. Kall M, Marcellin F, Harding R, Lazarus JV, Carrieri P. Patient-reported outcomes to enhance person-centred HIV care. *Lancet HIV*. 2019;7(1):e59-e68. doi: [10.1016/S2352-3018\(19\)30345-5](https://doi.org/10.1016/S2352-3018(19)30345-5)

**How to cite this article:** Izquierdo R, Suárez-García I, Marco-Sánchez C, et al. Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time. *HIV Med*. 2025;1-15. doi: [10.1111/hiv.13762](https://doi.org/10.1111/hiv.13762)

## APPENDIX A

\*Group authorship:

### CoRIS Executive Committee:

Santiago Moreno, Inma Jarrín, David Dalmau, M. Luisa Navarro, M. Isabel González, Federico García, Eva Poveda, Jose Antonio Iribarren, Félix Gutiérrez, Rafael Rubio, Francesc Vidal, Juan Berenguer, Juan González, M. Ángeles Muñoz-Fernández

**Centres and investigators involved in CoRIS cohort are listed below:**

### CoRIS Coordination Unit

Inmaculada Jarrín, Cristina Moreno, Marta Rava, Rebeca Izquierdo, Cristina Marco, Teresa Gómez-García

**BioBanK HIV Hospital General Universitario Gregorio Marañón**

M. Ángeles Muñoz-Fernández, Roxana Juárez

**Hospital General Universitario de Alicante (Alicante)**

Joaquín Portilla, Irene Portilla, Esperanza Merino, Gema García, Iván Agea, José Sánchez-Payá, Juan Carlos Rodríguez, Livia Giner, Sergio Reus, Vicente Boix, Diego Torrus, Verónica Pérez, Julia Portilla, Héctor Pinargote

**Hospital Universitario de Canarias (San Cristóbal de la Laguna)**

María Remedios Alemán, Ana López Lirola, Dácil García, Felicitas Díaz-Flores, M. Mar Alonso, Ricardo Pelazas, María Inmaculada Hernández, Lucía Romero, Abraham Bethencourt, Daniel Rodríguez

**Hospital Universitario Central de Asturias (Oviedo)**

Víctor Asensi, María Eugenia Rivas-Carmenado, Rebeca Cabo Magadan, Javier Díaz-Arias

### Hospital Universitario 12 de Octubre (Madrid)

Federico Pulido, Rafael Rubio, Otilia Bisbal, M. Asunción Hernando, David Rial, María de Lagarde, Adriana Pinto, Laura Bermejo, Mireia Santacreu, Roser Navarro, Juan Martín Torres

**Servicio de Enfermedades Infecciosas. Hospital Universitario Donostia. Instituto de Investigación BioDonostia (Donostia-San Sebastián)**

José Antonio Iribarren, M. José Aramburu, Xabier Camino, Miguel Ángel Goenaga, M. Jesús Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Xabier Kortajarena, Ignacio Álvarez-Rodríguez, Leire Gil, Francisco Carmona-Torre, Ana Bayona Carlos, Maialen Lekuona Sanz

### Hospital General Universitario De Elche (Elche)

Félix Gutiérrez, Catalina Robledano, Mar Masiá, Sergio Padilla, Araceli Adsuar, Rafael Pascual, Marta Fernández, Antonio Galiana, José Alberto García, Xavier Barber, Javier García Abellán, Guillermo Telenti, Lucía Guillén, Ángela Botella, Paula Mascarell, Mar Carvajal, Alba de la Rica, Carolina Ding, Lidia García-Sánchez, Nuria Ena, Leandro López, Jennifer Vallejo, Nieves Gonzalo-Jiménez,

Montserrat Ruiz, Christian Ledesma, Santiago López, María Espinosa, Ana Quiles, María Andreo

**Hospital Universitari Germans Trias i Pujol (Can Ruti) (Badalona)**

Roberto Muga, Arantza Sanvisens, Daniel Fuster

**Hospital General Universitario Gregorio Marañón (Madrid)**

Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Juan Berenguer, Margarita Ramírez, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Cristina Diez, Leire Pérez, Chiara Fanciulli, Saray Corral

**Hospital Universitari de Tarragona Joan XXIII (Tarragona)**

Joaquín Peraire, Anna Rull, Anna Martí, Consuelo Viladés, Beatriz Villar, Lluïsa Guillem, Montserrat Olona, Graciano García-Pardo, Frederic Gómez-Bertomeu, Verónica Alba, Silvia Chafino, Alba Sánchez

**Hospital Universitario y Politécnico de La Fe (Valencia)**

Marta Montero, María Tasias, Eva Calabuig, Miguel Salavert, Juan Fernández, Rosa Blanes

**Hospital Universitario La Paz/IdiPAZ (Madrid)**

Juan González-García, Ana Delgado-Hierro, José Ramón Arribas, Víctor Arribas, José Ignacio Bernardino, Carmen Busca, Joanna Cano-Smith, Julen Cadiñanos, Juan Miguel Castro, Luis Escosa, Iker Falces, Pedro Herranz, Víctor Hontañón, Alicia González-Baeza, M. Luz Martín-Carbonero, Mario Mayoral, Rafael Micán, Rosa de Miguel, Rocío Montejano, M<sup>a</sup> Luisa Montes, Luis Ramos-Ruperto, Berta Rodés, Talía Sainz, Elena Sendagorta, Eulalia Valencia, M. del Mar Arcos, Alejandro de Gea Grela, Carlos Oñoro López

**Hospital San Pedro Centro de Investigación Biomédica de La Rioja (CIBIR) (Logroño)**

José Ramón Blanco, Laura Pérez-Martínez, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz

**Hospital Universitario Miguel Servet (Zaragoza)**

Rosa Martínez, Desiré Gil, Álvaro Cecilio, Ruth Caballero, María Aranzazu Caudevilla

**Hospital Universitari Mutua Terrassa (Terrassa)**

David Dalmau, Marina Martínez, Angels Jaén, Mireia Cairó, Javier Martínez-Lacasa, Roser Font, Laura Gisbert

**Hospital Universitario de Navarra (Pamplona)**

María Rivero, Maider Goikoetxea, María Gracia, Carlos Ibero, Estela Moreno, Jesús Repáraz, Fernando Baigorria

**Parc Taulí Hospital Universitari (Sabadell)**

Gemma Navarro, Manel Cervantes García, Sonia Calzado Isbert, Marta Navarro Vilasaro

**Hospital Universitario de La Princesa (Madrid)**

Ignacio de los Santos, Alejandro de los Santos, Lucio García-Fraile, Enrique Martín, Ildefonso Sánchez-Cerrillo, Marta Calvet, Ana Barrios, Azucena Bautista,

Carmen Sáez, Marianela Ciudad, Ángela Gutiérrez, María Aguilera García

**Hospital Universitario Ramón y Cajal (Madrid)**

Santiago Moreno, Santos del Campo, José Luis Casado, Fernando Dronza, Ana Moreno, M. Jesús Pérez, Sergio Serrano-Villar, M<sup>a</sup> Jesús Vivancos, Javier Martínez-Sanz, Alejandro Vallejo, Matilde Sánchez-Conde, José Antonio Pérez-Molina, José Manuel Hermida, Erick De La Torre Tarazona, Elena Moreno, Laura Martín Pedraza, Claudio Díaz García, Jorge Díaz, Alejandro García, Raquel Ron

**Hospital General Universitario Reina Sofía (Murcia)**

Enrique Bernal, Antonia Alcaraz, Joaquín Bravo, Ángeles Muñoz, Cristina Tomás, Eva Oliver, David Selva, Eva García, Román González, Elena Guijarro, Rodrigo Martínez, María Dolores Hernández

**Hospital Universitario Clínico San Cecilio (Granada)**

Federico García, Clara Martínez, Leopoldo Muñoz Medina, Marta Álvarez, Natalia Chueca, David Vinuesa, Adolfo de Salazar, Ana Fuentes, Emilio Guirao, Laura Viñuela, Andrés Ruiz-Sancho, Francisco Anguita, Naya Faro, José Peregrina, Lucía Chaves, Marta Illescas, Valme Sánchez

**Centro Sanitario Sandoval (Madrid)**

Jorge Del Romero, Montserrat Raposo, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi, Begoña Baza, Eva Orviz

**Hospital Clínico Universitario de Santiago (Santiago de Compostela)**

Antonio Antela, Elena Losada

**Hospital Universitario Son Espases (Palma de Mallorca)**

Melchor Riera, María Peñaranda, M. Angels Ribas, Antoni A. Campins, Mercedes García-Gazalla, Francisco J. Fanjul, Javier Murillas, Francisco Homar, Helem H. Vilchez, Luisa Martín, Antoni Payeras

**Hospital Universitario Virgen de la Victoria (Málaga)**

Jesús Santos, María López, Cristina Gómez, Isabel Viciano, Rosario Palacios

**Hospital Universitario Virgen del Rocío (Sevilla)**

Luis Fernando López-Cortés, Nuria Espinosa, Cristina Roca, Silvia Llaves

**Hospital Universitario de Bellvitge (Hospitalet de Llobregat)**

Juan Manuel Tiraboschi, Arkaitz Imaz, María Saumoy

**Hospital Universitario Valle de Hebrón (Barcelona)**

Adrián Curran, Vicenç Falcó, Jordi Navarro, Joaquin Burgos, Paula Suanzes, Jorge García, Vicente Descalzo,

Patricia Álvarez, Bibiana Planas, Marta Sanchíz, Lucía Rodríguez, Arnau Monforte, Paola Vidovic

**Hospital Costa del Sol (Marbella)**

Julián Olalla, Javier Pérez, Alfonso del Arco, Javier de la Torre, José Luis Prada

**Hospital General Universitario Santa Lucía (Cartagena)**

Onofre Juan Martínez, Lorena Martínez, Francisco Jesús Vera, Josefina García, Begoña Alcaraz, Antonio Jesús Sánchez Guirao

**Complejo Hospitalario Universitario a Coruña (CHUAC) (A Coruña)**

Álvaro Mena, Berta Pernas, Pilar Vázquez, Soledad López, Brais Castelo

**Hospital Universitario Basurto (Bilbao)**

Sofía Ibarra, Guillermo García, Josu Mirena, Oscar Luis Ferrero, Josefina López, Mireia de la Peña, Miriam López, Iñigo López, Itxaso Lombide, Víctor Polo, Joana de Miguel, Beatriz Ruiz Estevez, Maite Ganchequi Aguirre, María Jesús Barberá Gracia

**Hospital Universitario Virgen de la Arrixaca (El Palmar)**

Carlos Galera, Marian Fernández, Helena Albendin, Antonia Castillo, Asunción Iborra, Antonio Moreno, M. Angustias Merlos, Inmaculada Chiclano

**Hospital de la Marina Baixa (La Vila Joiosa)**

Concha Amador, Francisco Pasquau, Concepción Gil, José Tomás Algado

**Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)**

Inés Suarez-García, Eduardo Malmierca, Patricia González-Ruano, M. Pilar Ruiz, José Francisco Pascual, Luz Balsalobre, Ángela Somodevilla

**Hospital Universitario de Jaén (Jaén)**

María de la Villa López, Mohamed Omar, Carmen Herrero

**Hospital Universitario San Agustín (Avilés)**

Miguel Alberto de Zárraga, Desirée Pérez

**Hospital Clínico San Carlos (Madrid)**

Vicente Estrada, Noemí Cabello, M. José Núñez, Iñigo Sagastagoitia, Reynaldo Homen, Ana Muñoz, Inés Armenteros Yeguas

**Hospital Universitario Fundación Jiménez Díaz (Madrid)**

Miguel Górgolas, Alfonso Cabello, Beatriz Álvarez, Laura Prieto, Aws Al-Hayani, Irene Carrillo

**Hospital Universitario Príncipe de Asturias (Alcalá de Henares)**

José Sanz, Alberto Arranz, Cristina Hernández, María Novella

**Hospital Clínico Universitario de Valencia (Valencia)**

M. José Galindo, Sandra Pérez Gómez, Ana Ferrer

**Hospital Reina Sofía (Córdoba)**

Antonio Rivero Román, Inma Ruíz, Antonio Rivero Juárez, Pedro López, Isabel Machuca, Mario Frias, Ángela Camacho, Ignacio Pérez, Diana Corona, Javier Manuel Caballero

**Hospital Universitario Severo Ochoa (Leganés)**

Rafael Rodríguez-Rosado Martínez-Echevarría, Rafael Torres

**Hospital Universitario Virgen de Valme (Sevilla)**

Juan Macías Sánchez, Pilar Rincón, Luis Miguel Real, Anais Corma, Alejandro González-Serna

**Hospital Álvaro Cunqueiro (Vigo)**

Eva Poveda, Alexandre Pérez, Luis Morano, Celia Miralles, Antonio Ocampo, Guillermo Pousada, María Gallego, Jacobo Alonso, Inés Martínez

**Hospital Clínico Universitario de Valladolid (Valladolid)**

Carlos Dueñas, Sara Gutiérrez, Marta de la Fuente López, Cristina Novoa, Xjoylin Egües, Pablo Telleria

**Hospital del Mar (Barcelona)**

Carlos Güerri Fernández, Claudia Navarro Valls, Juan Du, Agustín Marcos Blanco, Itziar Arrieta Aldea, Esperanza Cañas Ruan, Cecilia Canepa, Natalia García Giralt